Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of mavrilimumab (KPL-301) in giant cell arteritis
2018-001003-36Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Mavrilimumab + prednisone taper with Placebo + prednisone taper (2 arms). Primary endpoint: Time to flare by week 26 (intention-to-treat population). Started Jun 2018; status: completed.
02
Drugs
mavrilimumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2018-001003-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001003-36.